Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2005 Oct;89(10):1368-70.

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

Q D Nguyen, S Shah, S Tatlipinar, D V Do, E V Anden, P A Campochiaro
Case Reports

Bevacizumab suppresses choroidal neovascularisation caused by pathological myopia

Q D Nguyen et al. Br J Ophthalmol. 2005 Oct.

Erratum in

  • Br J Ophthalmol. 2006 Jan;90(1):125
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fundus appearance and optical coherence tomogram of patient 1 at baseline and after starting infusions of bevacizumab.
Figure 2
Figure 2
Fluorescein angiography of patient 1 at baseline and after starting infusions of bevacizumab.
Figure 3
Figure 3
Fundus appearance and optical coherence tomogram of patient 2 at baseline and after starting infusions of bevacizumab.
Figure 4
Figure 4
Fluorescein angiography of patient 2 at baseline and after starting infusions of bevacizumab.
See this image and copyright information in PMC

References

    1. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335–42. - PubMed
    1. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805–16. - PubMed
    1. Schwartz SD, Blumenkranz M, Rosenfeld PJ, et al. Safety of rhuFab V2, an anti-VEGF antibody fragment, as a single intravitreal injection in subjects with neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci (suppl) 2001;42:S522.

Substances